ALEPH-FARMS
19.1.2023 16:02:36 CET | Business Wire | Press release
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that Israeli Chief Rabbi, David Baruch Lau, has ruled its cultivated steak to be kosher, which means permitted for consumption by Jews under religious law. This ruling, coming from the leader of the Chief Rabbinate — a bellwether rabbinic council for religious certifications in Judaism — opens the door for Aleph Farms to receive a kosher certificate ahead of its market launch later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005570/en/
Cultivated thin cut steak by Aleph Farms (Photo: Business Wire)
“This ruling is meaningful not only for Aleph Farms as a company but also for the entire cultivated meat industry. It sets a foundation for an inclusive public discourse about the intersection of tradition and innovation in our society. At Aleph, we innovate in order to provide quality nutrition to anyone, anytime, anywhere in service of people and the planet, and that includes people with different culinary traditions,” said Didier Toubia, Co-Founder and CEO of Aleph Farms. “We’re excited that more groups of diners can enjoy our products regardless of their religion, helping us to advance our inclusive vision for food security and tap into different food cultures around the world”.
This ruling indicates an openness among religious authorities to certify cultivated meat products as appropriate to consume and paves the way forward as Aleph Farms works to get kosher certification for its production facility in Rehovot and its individual products. Aleph Farms is also in contact with Muslim, Hindu and other religious authorities to certify its products as a viable dietary option for groups that have different religious practices.
The global kosher beef market size is expected to reach approximately $100.85 billion USD by 2030. The growing preference for kosher beef in key countries such as the US, France and Israel, which have the highest Jewish populations and account for over 86% of the global Jewish population, is driving the market. In 2021, approximately 73.9% of Israel’s population was Jewish, making it a key market for kosher beef. This ruling indicates that upon market launch in Israel, expected in the near future, local authorities will likely confirm Aleph Farms cultivated steaks are kosher, enabling Jewish diners who observe kashrut to incorporate them into their diets.
Aleph Farms is working closely with regulatory agencies around the world as it prepares for the commercial launch of its first product, a cultivated thin-cut beef steak. The company also plans to produce different cuts of steak as well as cultivated collagen through additional proprietary capabilities. In all cases, Aleph Farms’ products are produced from starter cells that come from a fertilized egg, which was sourced from a premium Black Angus cow named Lucy – she lives on a breeding farm in California. From a one-time collection of Lucy’s fertilized egg, Aleph Farms can grow thousands of tons of cultivated meat without engineering or immortalizing cells, avoiding slaughter and acting as part of an inclusive solution for sustainable and secure food systems.
About Aleph Farms
Aleph Farms grows cultivated beef steaks from cells that are isolated from a living cow and not immortalized or genetically modified, avoiding slaughter and achieving reduced environmental impact. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub by Strauss Group, and Professor Shulamit Levenberg of the Technion - Israel Institute of Technology. Its vision is to ensure unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram, Twitter, Facebook or LinkedIn or visit www.aleph-farms.com. Access the Aleph Farms press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005570/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
